As FFA enhances TGF-β-promoted tumorigenesis through activation of ERK and USP9X, USP9X catalytic inhibitors such as WP1130 are regarded as effective treatments for obesity-related breast cancers [71]. This evidence concerns the gene USP9X and obesity due to melanocortin 4 receptor deficiency.